Publications – Melanoma Research Victoria https://melanomaresearchvic.com.au Fri, 16 Oct 2020 06:50:54 +0000 en-US hourly 1 https://melanomaresearchvic.com.au/wp-content/uploads/2017/12/cropped-favicon-32x32.png Publications – Melanoma Research Victoria https://melanomaresearchvic.com.au 32 32 Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer https://melanomaresearchvic.com.au/effect-of-cyclo-oxygenase-inhibitor-use-during-checkpoint-blockade-immunotherapy-in-patients-with-metastatic-melanoma-and-non-small-cell-lung-cancer Fri, 16 Oct 2020 06:49:59 +0000 https://melanomaresearchvic.com.au/?p=15816 Immune checkpoint inhibitors (ICIs) improve survival outcomes in metastatic melanoma and non-small cell lung cancer (NSCLC).

The post Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer appeared first on Melanoma Research Victoria.

]]>
Source: Doc Wire News,  October 2020

ABSTRACT

BACKGROUND: Immune checkpoint inhibitors (ICIs) improve survival outcomes in metastatic melanoma and non-small cell lung cancer (NSCLC). Preclinical evidence suggests that overexpression of cyclo-oxygenase-2 (COX2) in tumors facilitates immune evasion through prostaglandin E2 production and that COX inhibition synergizes with ICIs to promote antitumor T-cell activation. This study investigates whether concurrent COX inhibitor (COXi) use during ICI treatment compared with ICI alone is associated with improved time-to-progression (TTP), objective response rate (ORR) and overall survival (OS) in patients with metastatic melanoma and NSCLC.

METHODS: We retrospectively reviewed 90 metastatic melanoma and 37 metastatic NSCLC patients, treated with ICI between 2011 and 2019. Differences in TTP and OS by ICI+COXi versus ICI alone were compared using Kaplan-Meier and Cox regression. Interaction between ICI+COXi versus ICI alone and pretreatment neutrophil-lymphocyte ratio (NLR) was examined. Independent radiology review per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was performed.

READ THE ORIGINAL FULL ARTICLE

The post Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer appeared first on Melanoma Research Victoria.

]]>
The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-A multicenter retrospective study https://melanomaresearchvic.com.au/the-prognostic-significance-of-non-sentinel-lymph-node-metastasis-in-cutaneous-and-acral-melanoma-patients-a-multicenter-retrospective-study Fri, 16 Oct 2020 06:29:39 +0000 https://melanomaresearchvic.com.au/?p=15809 Whether non-sentinel lymph node (SLN)-positive melanoma patients can benefit from completion lymph node dissection (CLND) is still unclear.

The post The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-A multicenter retrospective study appeared first on Melanoma Research Victoria.

]]>
Source: Doc Wire News, October 2020

Background: Whether non-sentinel lymph node (SLN)-positive melanoma patients can benefit from completion lymph node dissection (CLND) is still unclear. The current study was performed to identify the prognostic role of non-SLN status in SLN-positive melanoma and to investigate the predictive factors of non-SLN metastasis in acral and cutaneous melanoma patients.

Methods: The records of 328 SLN-positive melanoma patients who underwent radical surgery at four cancer centers from September 2009 to August 2017 were reviewed. Clinicopathological data including age, gender, Clark level, Breslow index, ulceration, the number of positive SLNs, non-SLN status, and adjuvant therapy were included for survival analyses. Patients were followed up until death or June 30, 2019. Multivariable logistic regression modeling was performed to identify factors associated with non-SLN positivity. Log-rank analysis and Cox regression analysis were used to identify the prognostic factors for disease-free survival (DFS) and overall survival (OS).

READ THE ORIGINAL FULL ARTICLE

The post The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-A multicenter retrospective study appeared first on Melanoma Research Victoria.

]]>
Does very early timing of lymph node surgery after resection of the primary tumour improve the clinical outcome of patients with melanoma? https://melanomaresearchvic.com.au/does-very-early-timing-of-lymph-node-surgery-after-resection-of-the-primary-tumour-improve-the-clinical-outcome-of-patients-with-melanoma Mon, 12 Oct 2020 05:55:28 +0000 https://melanomaresearchvic.com.au/?p=15758 Researchers investigated if the clinical outcome of patients with cutaneous melanoma could be impacted by very early timing of sentinel lymph node biopsy (SLNB) post-resection of the primary tumour, or by timing of complete lymph node dissection (CLND) following SLNB, vs longer time intervals. Experts analyzed a cohort comprising 896 patients with melanoma who had […]

The post Does very early timing of lymph node surgery after resection of the primary tumour improve the clinical outcome of patients with melanoma? appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, September 2020

Researchers investigated if the clinical outcome of patients with cutaneous melanoma could be impacted by very early timing of sentinel lymph node biopsy (SLNB) post-resection of the primary tumour, or by timing of complete lymph node dissection (CLND) following SLNB, vs longer time intervals. Experts analyzed a cohort comprising 896 patients with melanoma who had undergone SLNB.

They defined an interval between primary resection and SLNB or between SLNB and CLND of up to 7 days as very early (VE-SLNB and VE-CLND, respectively).

They compared this time span with intervals of > 7 days.

READ THE ORIGINAL FULL ARTICLE

The post Does very early timing of lymph node surgery after resection of the primary tumour improve the clinical outcome of patients with melanoma? appeared first on Melanoma Research Victoria.

]]>
What is the accuracy of reflectance confocal microscopy (RCM) for the diagnosis of cutaneous malignant melanoma (MM) or melanoma in situ (MiS) in adults? https://melanomaresearchvic.com.au/what-is-the-accuracy-of-reflectance-confocal-microscopy-rcm-for-the-diagnosis-of-cutaneous-malignant-melanoma-mm-or-melanoma-in-situ-mis-in-adults Thu, 08 Oct 2020 06:42:38 +0000 https://melanomaresearchvic.com.au/?p=15744 Source: Cochrane Library, September 2020 Reviewers identified eight studies (9 evaluations, 1452 lesions, 370 cases of MM/MiS) that assessed the diagnostic accuracy of RCM, most commonly using histology as the reference standard (one study used unequivocal clinical and conventional dermoscopic criteria, and another used clinical follow-up in most participants). Across studies, average sensitivity ranged from […]

The post What is the accuracy of reflectance confocal microscopy (RCM) for the diagnosis of cutaneous malignant melanoma (MM) or melanoma in situ (MiS) in adults? appeared first on Melanoma Research Victoria.

]]>
Source: Cochrane Library, September 2020

Reviewers identified eight studies (9 evaluations, 1452 lesions, 370 cases of MM/MiS) that assessed the diagnostic accuracy of RCM, most commonly using histology as the reference standard (one study used unequivocal clinical and conventional dermoscopic criteria, and another used clinical follow-up in most participants).

Across studies, average sensitivity ranged from 63% to 100% (8/9 yielded sensitivities > 86%) and specificity from 57% to 95%.

Reviewers calculated a pooled estimate for specificity of 82% based on a fixed sensitivity of 90%.

READ THE ORIGINAL FULL ARTICLE

The post What is the accuracy of reflectance confocal microscopy (RCM) for the diagnosis of cutaneous malignant melanoma (MM) or melanoma in situ (MiS) in adults? appeared first on Melanoma Research Victoria.

]]>
What are the effects of statins used for prevention of melanoma? https://melanomaresearchvic.com.au/what-are-the-effects-of-statins-used-for-prevention-of-melanoma Thu, 08 Oct 2020 06:37:18 +0000 https://melanomaresearchvic.com.au/?p=15742 Most participants were people with coronary artery disease who had enrolled in trials of statin monotherapy primarily evaluating cardiovascular endpoints.

The post What are the effects of statins used for prevention of melanoma? appeared first on Melanoma Research Victoria.

]]>
Source: Cochrane Library, September 2020

Reviewers assessed the incidence of melanoma associated with statin use.

Most participants were people with coronary artery disease who had enrolled in trials of statin monotherapy primarily evaluating cardiovascular endpoints.

Studies were published between 1993 and 2002. Although the incidence of melanoma was lower with lovastatin, event rates were extremely low in all groups (< 1%).

READ THE ORIGINAL FULL ARTICLE

The post What are the effects of statins used for prevention of melanoma? appeared first on Melanoma Research Victoria.

]]>
Occupation and cutaneous melanoma: A 45-year historical cohort study of 14·9 million people in five Nordic countries https://melanomaresearchvic.com.au/occupation-and-cutaneous-melanoma-a-45year-historical-cohort-study-of-14%c2%b79-million-people-in-five-nordic-countries Wed, 07 Oct 2020 07:36:54 +0000 https://melanomaresearchvic.com.au/?p=15735 Since few prospective population?based studies have estimated the occupational variation in cutaneous melanoma (CM) risk over time, researchers sought to determine occupational variation in CM risk.

The post Occupation and cutaneous melanoma: A 45-year historical cohort study of 14·9 million people in five Nordic countries appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, September 2020

Since few prospective population-based studies have estimated the occupational variation in cutaneous melanoma (CM) risk over time, researchers sought to determine occupational variation in CM risk.

A historical prospective cohort study with a 45-year follow-up from 1961 to 2005 (Nordic Occupational Cancer Study, NOCCA) focused on record linkages between census and cancer registry data for Nordic residents aged 30 to 64 years in Denmark, Finland, Iceland, Norway, and Sweden.

Eighty-three thousand eight hundred ninety-eight incident cases of CM have been identified during a follow-up of 385 million person-years.

READ THE ORIGINAL FULL ARTICLE

The post Occupation and cutaneous melanoma: A 45-year historical cohort study of 14·9 million people in five Nordic countries appeared first on Melanoma Research Victoria.

]]>
Association of anti-programmed cell death 1 antibody treatment with risk of recurrence of toxic effects after immune-related adverse events of ipilimumab in patients with metastatic melanoma https://melanomaresearchvic.com.au/association-of-anti-programmed-cell-death-1-antibody-treatment-with-risk-of-recurrence-of-toxic-effects-after-immune-related-adverse-events-of-ipilimumab-in-patients-with-metastatic-melanoma Tue, 06 Oct 2020 08:10:21 +0000 https://melanomaresearchvic.com.au/?p=15733 In this cohort study involving 56 patients with metastatic melanoma, researchers sought to assess the risk of a recurrence of immune toxic effects correlated with anti-programmed cell death 1 antibody (anti–PD-1) therapy after discontinuation of ipilimumab monotherapy due to severe adverse events (AEs).

The post Association of anti-programmed cell death 1 antibody treatment with risk of recurrence of toxic effects after immune-related adverse events of ipilimumab in patients with metastatic melanoma appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, September 2020

In this cohort study involving 56 patients with metastatic melanoma, researchers sought to assess the risk of a recurrence of immune toxic effects correlated with anti-programmed cell death 1 antibody (anti–PD-1) therapy after discontinuation of ipilimumab monotherapy due to severe adverse events (AEs).

This investigation was carried out at 19 French melanoma referral centers involved patients with metastatic melanoma who experienced severe immune-related AEs following ipilimumab therapy and then were treated with anti–PD-1 therapy between February 1, 2013, and December 31, 2016.

In total, 12 patients (21%) felt grade 3 or 4 immune-related AEs, and among these patients, 4 (33%) presented with the same immune-related AE as with ipilimumab therapy.

READ THE ORIGINAL FULL ARTICLE

The post Association of anti-programmed cell death 1 antibody treatment with risk of recurrence of toxic effects after immune-related adverse events of ipilimumab in patients with metastatic melanoma appeared first on Melanoma Research Victoria.

]]>
Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma https://melanomaresearchvic.com.au/five-year-analysis-of-adjuvant-dabrafenib-plus-trametinib-in-stage-iii-melanoma Thu, 01 Oct 2020 08:12:45 +0000 https://melanomaresearchvic.com.au/?p=15712 Given that significantly longer relapse-free survival with 12 months of adjuvant dabrafenib plus trametinib vs placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations has been reported in the earlier reported primary analysis of this phase 3 trial, researchers undertook this investigation to corroborate the stability of the relapse-free survival […]

The post Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, September 2020

Given that significantly longer relapse-free survival with 12 months of adjuvant dabrafenib plus trametinib vs placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations has been reported in the earlier reported primary analysis of this phase 3 trial, researchers undertook this investigation to corroborate the stability of the relapse-free survival benefit.

They present 5-year outcomes for relapse-free survival as well as survival without distant metastasis as the site of the first relapse. Participants were 870 patients with resected stage III melanoma with BRAF V600E or V600K mutations.

These were randomized to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos.

READ THE ORIGINAL FULL ARTICLE

The post Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma appeared first on Melanoma Research Victoria.

]]>
Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018 https://melanomaresearchvic.com.au/metastatic-melanoma-patient-outcomes-since-introduction-of-immune-checkpoint-inhibitors-in-england-between-2014-and-2018 Wed, 30 Sep 2020 07:40:52 +0000 https://melanomaresearchvic.com.au/?p=15702 Researchers reviewed the prescribing of first?line checkpoint inhibitors (CPIs) for the treatment of patients with metastatic melanoma in England since their introduction in 2014 to better understand the clinical practice and used national databases to link outcomes such as survival and treatment toxicity of treated patients.

The post Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018 appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, September 2020

Researchers reviewed the prescribing of first?line checkpoint inhibitors (CPIs) for the treatment of patients with metastatic melanoma in England since their introduction in 2014 to better understand the clinical practice and used national databases to link outcomes such as survival and treatment toxicity of treated patients.

Five thousand four hundred sixty-five melanoma patients were diagnosed and treated with systemic anticancer therapy between April 2014 and March 2018, of which 2,322 received first?line CPIs.

READ THE ORIGINAL FULL ARTICLE

The post Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018 appeared first on Melanoma Research Victoria.

]]>
Predictors of long-term anxiety and depression in uveal melanoma survivors: A cross-lagged five-year analysis https://melanomaresearchvic.com.au/predictors-of-long%e2%80%90term-anxiety-and-depression-in-uveal-melanoma-survivors-a-cross%e2%80%90lagged-five%e2%80%90year-analysis Thu, 24 Sep 2020 07:59:41 +0000 https://melanomaresearchvic.com.au/?p=15671 Data were obtained from sample of 453 uveal melanoma survivors who completed observations 6?, 12?, 24?, 36?, 48? and 60?months postdiagnosis and missed no two consecutive observations.

The post Predictors of long-term anxiety and depression in uveal melanoma survivors: A cross-lagged five-year analysis appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, August 2020

As anxiety and depression are commonly reported in cancer survivors in long-term, researchers here examined three potential causal paths: (a) a direct path in which anxiety and depression arise due to concerns regarding physical symptoms and functional problems and fear of cancer recurrence (FCR) emerging during survivorship, (b) an indirect path whereby effects of concerns regarding physical symptoms and functional problems on anxiety and depression are mediated by FCR, and (c) a reciprocal path whereby anxiety and depression cause concerns regarding physical symptoms and functional problems and FCR, which aggravate later anxiety and depression.

Data were obtained from sample of 453 uveal melanoma survivors who completed observations 6-, 12-, 24-, 36-, 48- and 60-months postdiagnosis and missed no two consecutive observations.

READ THE ORIGINAL FULL ARTICLE

 

The post Predictors of long-term anxiety and depression in uveal melanoma survivors: A cross-lagged five-year analysis appeared first on Melanoma Research Victoria.

]]>